Angela M DeMichele, MD MSCE
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Graduate Group Affiliations
Contact information
Perelman Center for Advanced Medicine
3 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
3 West Pavilion
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
Fax: 215-615-3349
Email:
dma@mail.med.upenn.edu
dma@mail.med.upenn.edu
Education:
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Permanent linkB.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Description of Research Expertise
breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiologySelected Publications
DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benzz CC, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster PN, Olopade OI, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman LJ.: Developing safety criteria for introducing new agents into neoadjuvant trials. Clinical Cancer Research Page: [Epub ahead of print] March 2013.Yang X, Zhong X, Tanyi JL, Shen J, Xu C, Gao P, Zheng TM, DeMichele A, Zhang L.: mir-30d regulated multiple genes in the autophagy pathway and impairs autophagy process in human cancer. Biochem Biophys Res Commun 431(3): 617-22, February 2013.
Busch DR, Choe R, Rosen MA, Guo W, Durduran T, Feldman MD, Mies C, Czerniecki BJ, Tchou J, Demichele A, Schnall MD, Yodh AG.: Optical malignancy parameters for monitoring progression of breast cancer neoadjuvant chemotherapy. Biomed Opt Express 4(1): 105-21, January 2013.
Desai K, Mao JJ, Su I, DeMichele A, Li Q, Xie SX, Gehrman PR: Prevalence and risk factors for insomnia among breast cancer patients on aromatase inhibitors. Support Care Cancer January 2013.
Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhor C, Hofler H, Esserman L, on behalf of the I-SPY 1 Trial Investigators, Liotta LA, Becker KF, Petricion EF 3rd: Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping. Clinical Cancer Research 18(23): 6426-35, December 2012.
Pryma DA, DeMichele A, Mankoff DA: Evaluting the Impact of New Imaging Tests: Promises and Pitfalls. Journal of the National Cancer Institute 104(24): 1857-8, December 2012.
Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ: Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Research and Treatment [Epub ahead of print], December 2012.
Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Jo Chien A, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L: Adaptive Trials in the Neoadjuvant Setting: A Model to Safely Tailor Care While Accelerating Drug Development. Journal of Clinical Oncology 30(36): 4584-6, December 2012.
Speck RM, DeMichele A, Farrar JT, Hennessy S, Mao JJ, Stineman MG, Barg FK: Scope of symptoms and self-management strategies for chemotherapy-induced peripheral neuropathy in breast cancer patients. Supportive Care in Cancer 20(10): 2433-9, October 2012.
Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton ME, Hudis C, Gray J, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler LJ, Chhieng D, Singh B, Mies C, Rabban J, Chen Y, Giri D, van ‘t Veer L, and Hylton N on behalf of the I-SPY 1 TRIAL Investigators.: Pathologic Complete Response Predicts Recurrence-Free Survival More Effectively by Cancer Subset: Results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Journal of Clinical Oncology 30(26): 3242-9, September 2012.